Core One Labs Completes Milestone Acquisition of Akome Biotech apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Months after submitting an application to uplist its shares from Toronto’s NEO exchange,
MindMed (OTCQB:MMEDF) confirmed it will commence trading on the Nasdaq Capital Market under the ticker symbol “MNMD” on April 27.
MindMed will continue to be listed on the NEO exchange, and its subordinate voting shares will remain listed on the OTCQB until trading on the Nasdaq begins.
“We believe this listing will increase our visibility in the marketplace, improve liquidity, broaden and diversify our shareholder base, and ultimately enhance long-term shareholder value,” said JR Rahn, CEO and co-founder of MindMed.
MindMed shares spiked 65% on Friday, from $2.13 to $3.52 at market close.
Core One Labs Vocan Biotechnologies Enters into Collaborative Research Agreement with UBC apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for .
Core One Labs Inc.April 21, 2021 GMT
VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”) a life sciences research and technology company focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy is pleased to announce its wholly owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has initiated the engineering and design of a proprietary enzymatic production system for the manufacturing of API-grade N,N-dimethyltryptamine (DMT). DMT, a naturally occurring psychedelic substance, is currently under clinical investigation for the treatment of certain mood disorders. The compound is a primary component o